Invasive candidiasis is the most common invasive fungal infection and remains associated with substantial morbidity and mortality. Despite updated guidelines and new antifungal options, gaps persist in optimal initial therapy selection, source control, and transitions of care, particularly when patients have chronic or disseminated candidiasis. This activity, based on a live Town Hall held on September 29, 2025, uses real-world case studies and a patient perspective to highlight practical strategies for improving clinical decision-making and patient-centered outcomes for invasive candidiasis.
Release Date: 11/26/2025
Expiration Date: 11/25/2026
Estimated Time to Complete the Activity: 1.5 hrs
Media: Interactive, text-based activity
Upon completing this activity, the participant should be better able to:
This initiative is intended for infectious diseases physicians, critical care physicians, hospitalists, hematologists/oncologists, surgeons, pathologists/clinical microbiologists, pharmacists, pediatric infectious disease specialists, transplant specialists, advanced practice providers, and nurses and other healthcare professionals responsible for the management of invasive fungal infections.
In support of improving patient care, this activity has been planned and implemented by Partners for Advancing Clinical Education (Partners); Terranova Medica, LLC; and the Mycoses Study Group Education & Research Consortium (MSGERC). Partners is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC) to provide continuing education for the healthcare team.
Partners designates this enduring material for a maximum of 1.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
The maximum number of hours awarded for this Continuing Nursing Education is 1.5 contact hours.
Partners designates this continuing education activity for 1.5 contact hours (0.15 CEUs) of the Accreditation Council for Pharmacy Education.
Universal Activity Number - JA4008073-9999-25-374-H01-P
Type of Activity: Application
Partners for Advancing Clinical Education (Partners) requires every individual in a position to control educational content to disclose all financial relationships with ineligible companies that have occurred within the past 24 months. Ineligible companies are organizations whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients.
All relevant financial relationships for anyone with the ability to control the content of this educational activity are listed below and have been mitigated according to Partners policies. Others involved in the planning of this activity have no relevant financial relationships.
Peter G. Pappas, MD, FACP
INDEPENDENT CONTRACTOR (DATA REVIEW): F2G
INVESTIGATOR: Astellas, IMMY
CONSULTANT, ADVISOR: Melinta Therapeutics, Basilea Pharmaceutica
Sarah Hammond, MD
INVESTIGATOR: Cidara/Mundipharma, F2G, Scynexis, and GSK
CONSULTANT: Melinta, Pfizer, Roche, Seres Therapeutics, Takeda, and Treeline Biosciences
Michael Mansour, MD, PhD
INVESTIGATOR: Karius, ThermoFisher, Genentech, Roche, and CytoVale
CONSULTANT: Roche and Vericel
WRITER: UpToDate
The Terranova planners (Lisa A. Tushla, PhD, H[ASCP], and Marisa F. Baldassano, MD) as well as the Partners planners have no relevant financial relationship(s) to disclose with ineligible companies.
Participation in this self-study activity should be completed in approximately 1.5 hours. To successfully complete this activity and receive CE credit, learners must follow these steps during the period from 11/26/2025 through 11/25/2026:
If you wish to receive acknowledgment for completing this activity, please follow the steps below:
You must receive a test score of at least 75% and respond to all evaluation questions to receive a certificate.
For Pharmacists: Upon successfully completing the post-assessment, your credit will be submitted to CPE Monitor. Please check your NABP account within thirty (30) days to make sure the credit has posted.
Internet
To participate, you will need access to a computer (either MAC or PC), tablet, or smart phone, with a Chrome (version 22.0.1229.94 or greater) web browser, Firefox (version 3.6 or greater) web browser or an Internet Explorer (version 8.0 or greater) web browser, JavaScript enabled, connected to the Internet (high speed connection preferred).
Terranova Medica, LLC, and Partners are committed to protecting the privacy of those who choose to participate in activities on funguscme.org. This information below describes our security policies for safeguarding personal information as well as the rationale for collection and use of personal information.
Security/safeguarding personal information
This website has physical and procedural safeguards in place to prevent unauthorized access to personal information used to access this website.
Collection and use of personal information
Terranova Medica, LLC, and Partners do not transfer, sell, or share personal information with outside parties. We will not disclose the information unless required in a legal proceeding.
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications. The opinions expressed in the educational activity are those of the faculty and do not necessarily reflect the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discuss suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review to applicable manufacturer’s product information, and comparison with recommendations of other authorities.
There is no fee for this activity.
Jointly provided by Partners; Terranova Medica, LLC; and the MSGERC.
This activity is supported by an independent educational grant from Melinta Therapeutics.
For further information, contact Tom Davis (tdavis@terranovamedica.com).
For additional information about the accreditation of this activity, visit https://partnersed.com.
Copyright © 2025 PARTNERS, Terranova Medica, LLC, and MSGERC.
